JPH11158066A - Pharmaceutical product containing ibuprofen - Google Patents
Pharmaceutical product containing ibuprofenInfo
- Publication number
- JPH11158066A JPH11158066A JP34195097A JP34195097A JPH11158066A JP H11158066 A JPH11158066 A JP H11158066A JP 34195097 A JP34195097 A JP 34195097A JP 34195097 A JP34195097 A JP 34195097A JP H11158066 A JPH11158066 A JP H11158066A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- acetaminophen
- weight
- pharmaceutical
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、イブプロフェン（ibup
rofen）を含有する新規な医薬製剤に関する。The present invention relates to ibuprofen (ibup
rofen).
【０００２】[0002]
【従来の技術】イブプロフェンは、解熱、鎮痛、抗炎症
作用を有し、現在、世界中で使われている非ステロイド
性解熱鎮痛剤であるが、鎮痛効果が比較的マイルドであ
ることおよび胃部不快感、胃痛などの副作用を発生しや
すいことから、イブプロフェンの鎮痛効果自体の増強を
図る目的で、または、その胃腸障害を軽減する目的で、
種々の薬効成分との配合が試みられている。例えば、イ
ブプロフェンとブセチンなどのアニリン誘導体系解熱鎮
痛剤の配合剤（特公昭６４−８６０２号公報）、イブプ
ロフェンと鎮痛量に満たない量のアセトアミノフェンを
組み合わせた薬学組成物（特開昭５９−１０４３１５号
公報）、イブプロフェンとカフェイン含有の薬学的組成
物（特公平１−２４１３１号公報）、イブプロフェン、
アセトアミノフェンおよびマグネシウム系制酸剤の配合
剤（特開平５−１４８１３９号公報）およびイブプロフ
ェンとトラネキサム酸の配合剤（特開平９−４８７２８
号公報）が提案されている。BACKGROUND OF THE INVENTION Ibuprofen has antipyretic, analgesic and anti-inflammatory effects and is currently a non-steroidal antipyretic analgesic used worldwide. Since it is easy to cause side effects such as discomfort and stomach pain, for the purpose of enhancing the analgesic effect itself of ibuprofen, or for the purpose of reducing its gastrointestinal disorders,
Attempts have been made to blend them with various medicinal ingredients. For example, a combination preparation of an antipyretic analgesic based on an aniline derivative such as ibuprofen and busetin (Japanese Patent Publication No. 64-8602), a pharmaceutical composition comprising a combination of ibuprofen and an acetaminophen in an amount less than the analgesic amount (Japanese Patent Laid-Open No. 59-1984). No. 104315), a pharmaceutical composition containing ibuprofen and caffeine (Japanese Patent Publication No. 1-24131), ibuprofen,
A compounding agent of acetaminophen and a magnesium-based antacid (JP-A-5-148139) and a compounding agent of ibuprofen and tranexamic acid (JP-A-9-48728)
Publication).
【０００３】一方、アセトアミノフェンは、安全性の高
い解熱鎮痛剤として広く用いられており、上記従来技術
に挙げたようにイブプロフェンとの配合も試みられてい
る。しかし、イブプロフェンの鎮痛効果の増強および胃
腸障害の軽減の両者を満足するために、イブプロフェン
とアセトアミノフェンのみを薬効成分として含有し、両
者を好ましい比率で配合させた製剤と言えるものはまだ
見出されていない。On the other hand, acetaminophen is widely used as a highly safe antipyretic analgesic, and attempts have been made to mix it with ibuprofen as mentioned in the above prior art. However, in order to satisfy both the enhancement of the analgesic effect of ibuprofen and the reduction of gastrointestinal disorders, a formulation containing only ibuprofen and acetaminophen as medicinal ingredients and combining them in a preferable ratio has not yet been found. It has not been.
【０００４】[0004]
【発明が解決しようとする課題・課題を解決するための
手段】本発明の課題は、イブプロフェンの鎮痛効果の増
強および胃腸障害の軽減の両者を満足するために、イブ
プロフェンとアセトアミノフェンのみを薬効成分として
含有し、両者を好ましい比率で配合させた製剤を提供す
ることにある。本発明者らは、イブプロフェンとアセト
アミノフェンの配合について種々検討を加えた結果、両
者を特定の比率で配合することにより、イブプロフェン
の鎮痛効果の増強と同時に胃腸障害の軽減が達成できる
ことを見出し、さらに検討を重ねて本発明を完成した。SUMMARY OF THE INVENTION An object of the present invention is to provide a pharmaceutical composition containing only ibuprofen and acetaminophen in order to satisfy both the analgesic effect of ibuprofen and the reduction of gastrointestinal disorders. It is an object of the present invention to provide a preparation containing both components as a component and blending them in a preferable ratio. The present inventors have made various studies on the combination of ibuprofen and acetaminophen, and found that by combining both at a specific ratio, the analgesic effect of ibuprofen can be enhanced and gastrointestinal disorders can be reduced at the same time. After further studies, the present invention was completed.
【０００５】[0005]
【発明の実施態様】本発明の具体的な実施態様として
は、 １）薬効成分として、イブプロフェンおよびアセトアミ
ノフェンのみを含有し、イブプロフェン１重量部に対し
て、アセトアミノフェンを０．４０〜０．６０重量部配
合した医薬製剤；および ２）アセトアミノフェンを０．４０〜０．５０重量部配
合した上記１）記載の医薬製剤などが挙げられる。DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS As a specific embodiment of the present invention, 1) only ibuprofen and acetaminophen are contained as active ingredients, and 0.40-0 acetaminophen is added to 1 part by weight of ibuprofen. .60 parts by weight; and 2) 0.40 to 0.50 parts by weight of acetaminophen as described in 1) above.
【０００６】上記における薬効成分とは、医薬品に含有
される有効成分を意味し、当該有効成分の具体的な物質
としては、例えば、１９９７年１０月版医療薬日本医薬
品集（薬業時報社発行）の五十音索引またはアルファベ
ット索引に収載されている物質が挙げられる。本発明の
医薬製剤においては、薬効成分として、イブプロフェン
およびアセトアミノフェンのみを含有する。上記におけ
るイブプロフェンとは、２−（４−イソブチルフェニ
ル）プロピオン酸の化学名を有する物質で、「第１３改
正日本薬局方」（以下「局方」という）等に収載されて
いる薬効成分である。上記におけるアセトアミノフェン
とは、Ｎ−（４−ヒドロキシフェニル）アセタミドの化
学名を有する物質で、局方等に収載されている薬効成分
である。[0006] The above-mentioned medicinal ingredient means an active ingredient contained in a drug, and specific examples of the active ingredient include, for example, Japanese Pharmaceutical Collection, October 1997 edition of Pharmaceutical Pharmaceutical Co., Ltd. ) In the Japanese syllabary index or the alphabetical index. The pharmaceutical preparation of the present invention contains only ibuprofen and acetaminophen as active ingredients. The ibuprofen in the above is a substance having a chemical name of 2- (4-isobutylphenyl) propionic acid, and is a medicinal ingredient listed in the “13th Revised Japanese Pharmacopoeia” (hereinafter referred to as “the Pharmacopoeia”) and the like. . The acetaminophen in the above is a substance having a chemical name of N- (4-hydroxyphenyl) acetamide, and is a medicinal ingredient listed in a pharmacopeia or the like.
【０００７】本発明の医薬製剤においては、薬効成分と
して、イブプロフェンおよびアセトアミノフェンのみを
含有し、両者の比率は、イブプロフェン１重量部に対し
て、アセトアミノフェンを０．４０〜０．６０重量部配
合したものが好ましく、アセトアミノフェンを０．４０
〜０．５０重量部配合したものがさらに好ましい。イブ
プロフェンとアセトアミノフェンを当該比率で配合する
ことにより、イブプロフェンの鎮痛効果の増強と同時に
胃腸障害の軽減が達成できる。The pharmaceutical preparation of the present invention contains only ibuprofen and acetaminophen as the active ingredients, and the ratio of both is 0.40 to 0.60% by weight of acetaminophen per 1 part by weight of ibuprofen. Of acetaminophen in 0.40 parts by weight.
More preferably, a composition containing 0.50 parts by weight is used. By mixing ibuprofen and acetaminophen at the above ratio, the analgesic effect of ibuprofen can be enhanced and gastrointestinal disorders can be reduced at the same time.
【０００８】上記における医薬製剤とは、錠剤、顆粒
剤、散剤、硬カプセル剤、軟カプセル剤、トローチ剤、
シロップ剤および経口用懸濁剤など経口投与に適した固
形製剤および液剤を意味する。本発明の医薬製剤は、上
記したイブプロフェンおよびアセトアミノフェンのほか
に、上記医薬製剤に適した製剤添加物を含有することが
できる。当該製剤添加物とは、上記医薬製剤で挙げた剤
型の医薬品を製造する上で通常使用される添加剤をい
い、例えば、局方および「医薬品添加物事典」（薬事日
報社、1994年1月14日発行）に収載されている賦形剤、
結合剤、崩壊剤、滑沢剤、コーティング剤などから錠
剤、顆粒剤、散剤、硬カプセル剤、軟カプセル剤、トロ
ーチ剤、シロップ剤および経口用懸濁剤などに適したも
のが選択される。当該製剤添加物の具体的な物質として
は、デンプン、コーンスターチ、結晶セルロース、乳
糖、白糖、ブドウ糖、マンニトール、ソルビトール、キ
シリトール、グリセリン、ゼラチン、寒天、アラビアゴ
ム、ヒドロキシプロピルセルロース、低置換度ヒドロキ
シプロピルセルロース、メチルセルロース、カルボキシ
メチルセルロース、ポリビニルピロリドン、カルボキシ
メチルセルロースナトリウム、カルボキシメチルセルロ
ースカルシウム、ステアリン酸マグネシウム、タルク、
水素添加植物油、マクロゴール、ベントナイト、ヘクト
ライト、トラガントおよびアルギン酸ナトリウムなどが
挙げられる。本発明の医薬製剤は、例えば、局方に記載
の錠剤、顆粒剤、散剤、硬カプセル剤、軟カプセル剤、
トローチ剤、シロップ剤および経口用懸濁剤の製造法に
従って製造することができる。The above-mentioned pharmaceutical preparations include tablets, granules, powders, hard capsules, soft capsules, troches,
Solid preparations and liquid preparations suitable for oral administration, such as syrups and oral suspensions. The pharmaceutical preparation of the present invention can contain, in addition to ibuprofen and acetaminophen described above, formulation additives suitable for the pharmaceutical preparation. The pharmaceutical additive refers to an additive usually used for producing a pharmaceutical of the dosage form mentioned in the above pharmaceutical preparation, and includes, for example, the Pharmacopoeia and the “Drug Encyclopedia” (Yakuji Nippo, Jan. 1994). Excipients listed on March 14)
Tablets, granules, powders, hard capsules, soft capsules, troches, syrups, oral suspensions, and the like are selected from binders, disintegrants, lubricants, coating agents, and the like. Specific substances of the pharmaceutical additives include starch, corn starch, crystalline cellulose, lactose, sucrose, glucose, mannitol, sorbitol, xylitol, glycerin, gelatin, agar, gum arabic, hydroxypropylcellulose, low-substituted hydroxypropylcellulose , Methylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, carboxymethylcellulose sodium, carboxymethylcellulose calcium, magnesium stearate, talc,
Hydrogenated vegetable oils, macrogol, bentonite, hectorite, tragacanth, sodium alginate and the like. Pharmaceutical preparations of the present invention include, for example, tablets, granules, powders, hard capsules, soft capsules,
It can be produced according to the method for producing troches, syrups and oral suspensions.
【０００９】本発明の医薬製剤は、頭痛、歯痛、抜歯後
疼痛、咽頭痛、関節痛、神経痛、腰痛、筋肉痛、生理痛
などの鎮痛、発熱時の解熱などに対して有効である。本
発明の医薬製剤は、通常一日に１〜数回に分けて経口投
与されるが、本発明の医薬製剤におけるイブプロフェン
の量は、イブプロフェンの投与量が、成人の場合、１０
０〜１０００ｍｇ／日、好ましくは２００〜８００ｍｇ
／日、より好ましくは３００〜６００ｍｇ／日程度とな
るように配合するのがよい。当該イブプロフェンの投与
量は、小児を含めて、患者の年齢、体重、症状により適
宜増減できる。また、本発明の医薬製剤におけるアセト
アミノフェンの量は、前記イブプロフェンの配合量に応
じて、イブプロフェン１重量部に対して０．４０〜０．
６０重量部、好ましくは０．４０〜０．５０重量部配合
される。以下に、試験例および実施例に基づいて本発明
をさらに詳細に説明するが、本発明はこれらの例示に限
定されない。The pharmaceutical preparation of the present invention is effective for relieving headache, toothache, post-extraction pain, sore throat, arthralgia, neuralgia, back pain, muscle pain, menstrual pain, etc., and fever relief during fever. The pharmaceutical preparation of the present invention is usually orally administered once or several times a day, but the amount of ibuprofen in the pharmaceutical preparation of the present invention is 10% when the dose of ibuprofen is adult.
0-1000 mg / day, preferably 200-800 mg
/ Day, more preferably about 300 to 600 mg / day. The dose of ibuprofen can be appropriately increased or decreased depending on the age, weight, and symptoms of the patient, including the child. In addition, the amount of acetaminophen in the pharmaceutical preparation of the present invention ranges from 0.40 to 0.1 to 1 part by weight of ibuprofen depending on the amount of ibuprofen.
60 parts by weight, preferably 0.40 to 0.50 parts by weight. Hereinafter, the present invention will be described in more detail based on Test Examples and Examples, but the present invention is not limited to these exemplifications.
【００１０】試験例１ 酢酸ライジング法による鎮痛効
果試験 ＜試験法＞１群６〜１２匹のマウスに、１％アラビアゴ
ム溶液に用時懸濁した被験薬を、０．１ｍｌ／１０ｇ体
重の割合で経口投与し、３０分後に０．６％酢酸を０．
１ｍｌ／１０ｇ体重の割合で腹腔内投与した。その後、
２０分間のライジング数を測定し、１％アラビアゴム溶
液のみを投与した対照群に対する抑制率を算出し、これ
に基づいてＥＤ50値を求めた。ＥＤ50値は、Litchfield
& Wilcoxon法によって算出し、結果を表１に示した。
表１には、Gaddumの式（Pharmacology、Oxford Univers
ity Press、London、1953）より算出したＥＤ50値の理
論値を合わせて示した。Test Example 1 Analgesic effect test by acetic acid writhing method <Test method> A test drug suspended in a 1% gum arabic solution in groups of 6 to 12 mice at a rate of 0.1 ml / 10 g body weight was used. Orally after 30 minutes, 0.6% acetic acid was added to 0.1%.
It was intraperitoneally administered at a rate of 1 ml / 10 g body weight. afterwards,
The number of rises for 20 minutes was measured, and the inhibition ratio with respect to the control group to which only a 1% gum arabic solution was administered was calculated. Based on this, the ED 50 value was obtained. The ED 50 value is Litchfield
& Calculated by the Wilcoxon method, and the results are shown in Table 1.
Table 1 shows the Gaddum formula (Pharmacology, Oxford Univers
ED 50 value calculated from the above-mentioned information is also shown.
【００１１】[0011]
【表１】 [Table 1]
【００１２】＜結果＞表１より、イブプロフェン１重量
部に対してアセトアミノフェンを０．４３および０．５
０重量部配合した場合、Gaddumの理論値の約１．５〜２
倍の強さの鎮痛活性が認められ、当該配合比率におい
て、優れた鎮痛増強作用を示すことがわかる。<Results> According to Table 1, 0.43 and 0.5 parts of acetaminophen were added to 1 part by weight of ibuprofen.
When 0 parts by weight are blended, the theoretical value of Gaddum is about 1.5 to 2
An analgesic activity twice as strong was observed, indicating that the compounding ratio exhibited an excellent analgesic enhancing effect.
【００１３】試験例２ 胃障害抑制作用 ＜試験法＞１群４〜６匹のラットに被験薬を経口投与
し、３．５時間後に１．０％ポンタミンスカイブルー１
ｍｌを静脈内投与した。その３０分後に胃を摘出し、５
％ホルマリンで固定した後、大弯側に沿って開いた。各
個体毎に障害（びらん）の長さの和を求めて胃障害度と
した。結果を表２および表３に示した。Test Example 2 Inhibitory effect on stomach damage <Test method> A test drug was orally administered to 4 to 6 rats per group, and after 3.5 hours, 1.0% pontamine sky blue 1
ml was administered intravenously. 30 minutes after that, the stomach is removed and 5
After fixing with% formalin, it was opened along the greater curvature. The sum of the lengths of the disorders (erosions) was determined for each individual, and the sum was used as the degree of gastric damage. The results are shown in Tables 2 and 3.
【００１４】[0014]
【表２】 [Table 2]
【００１５】[0015]
【表３】 [Table 3]
【００１６】＜結果＞表２および表３より、イブプロフ
ェン１重量部に対してアセトアミノフェンを０．４３お
よび０．５０重量部配合した場合、胃障害度はイブプロ
フェン単独の場合の約１／２に近く、当該配合比率にお
いて優れた胃障害抑制作用を示すことがわかる。<Results> According to Tables 2 and 3, when 0.43 and 0.50 parts by weight of acetaminophen were added to 1 part by weight of ibuprofen, the degree of gastric damage was about 1/2 that of the case of ibuprofen alone. It can be seen that the compounding ratio shows an excellent gastric disorder-suppressing action at this ratio.
【００１７】実施例１ 錠剤１錠中の処方例（全量１３４ｍｇ）：イブプロフェ
ン７５ｍｇ、アセトアミノフェン３２．５ｍｇ、コーン
スターチ１６．１５ｇ、低置換度ヒドロキシプロピルセ
ルロース７．００ｍｇおよびデンプン３．３５ｍｇ上記
処方について、造粒規模を６０００錠（８０４ｇ）に設
定し、バーチカルグラニュレータで造粒する。得られた
顆粒をスピドミルで整粒後、通風式箱形乾燥機で乾燥し
整粒末を得、圧縮成型して錠剤を製した。Example 1 Formulation example per tablet (134 mg in total): 75 mg of ibuprofen, 32.5 mg of acetaminophen, 16.15 g of corn starch, 7.00 mg of low-substituted hydroxypropylcellulose and 3.35 mg of starch The granulation scale is set to 6000 tablets (804 g), and granulation is performed using a vertical granulator. The obtained granules were sized by a spid mill and dried by a ventilated box drier to obtain sized powders, which were compression molded to produce tablets.
【００１８】実施例２ カプセル剤１カプセル中の処方（全量１５０ｍｇ）：イ
ブプロフェン７５ｍｇ、アセトアミノフェン３７．５ｍ
ｇ、コーンスターチ３７．５ｍｇ上記処方について、局
方製剤総則記載の公知方法に従って、カプセル剤を製し
た。 実施例３ 顆粒剤１包中の処方（全量４４０ｍｇ）：イブプロフェ
ン７５ｍｇ、アセトアミノフェン３２．５ｍｇ、乳糖３
００ｍｇ、結晶セルロース３０ｍｇ、アラビアゴム２．
５ｍｇ上記処方について、局方製剤総則記載の公知方法
に従って、顆粒剤を製した。Example 2 Capsule Formulation in 1 capsule (total amount 150 mg): 75 mg of ibuprofen, 37.5 m of acetaminophen
g, 37.5 mg of corn starch For the above formulation, a capsule was prepared according to a known method described in the General Rules for Pharmaceutical Preparations. Example 3 Formulation in one package of granules (total amount: 440 mg): 75 mg of ibuprofen, 32.5 mg of acetaminophen, lactose 3
1.00 mg, crystalline cellulose 30 mg, gum arabic
About 5 mg of the above-mentioned formulation, a granule was produced according to a known method described in the general rules of preparations in Japanese Pharmacopoeia.
【００１９】[0019]
【発明の効果】本発明は、イブプロフェン１重量部に対
して、アセトアミノフェンを０．４０〜０．６０重量
部、より好ましくは０．４０〜０．５０重量部配合する
ことにより、薬効成分として、イブプロフェンおよびア
セトアミノフェンのみを含有し、イブプロフェンの鎮痛
効果の増強と胃腸障害の軽減の両者を満足する医薬製剤
の提供を可能とする。According to the present invention, a pharmacologically active ingredient is obtained by blending 0.40 to 0.60 part by weight, more preferably 0.40 to 0.50 part by weight, of acetaminophen with respect to 1 part by weight of ibuprofen. Thus, it is possible to provide a pharmaceutical preparation containing only ibuprofen and acetaminophen and satisfying both the analgesic effect of ibuprofen and the reduction of gastrointestinal disorders.
Claims (2)
びアセトアミノフェンのみを含有し、イブプロフェン１
重量部に対して、アセトアミノフェンを０．４０〜０．
６０重量部配合した医薬製剤。1. Ibuprofen 1 containing only ibuprofen and acetaminophen as medicinal ingredients
Acetaminophen was added in an amount of 0.40 to 0.4 parts by weight based on parts by weight.
A pharmaceutical preparation containing 60 parts by weight.
５０重量部配合した請求項１記載の医薬製剤。2. Acetaminophen in an amount of 0.40 to 0.1.
The pharmaceutical preparation according to claim 1, which is blended in an amount of 50 parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34195097A JP3982889B2 (en) | 1997-11-28 | 1997-11-28 | Pharmaceutical preparations containing ibuprofen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34195097A JP3982889B2 (en) | 1997-11-28 | 1997-11-28 | Pharmaceutical preparations containing ibuprofen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007043946A Division JP2007137896A (en) | 2007-02-23 | 2007-02-23 | Ibuprofen-containing pharmaceutical preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11158066A true JPH11158066A (en) | 1999-06-15 |
| JP3982889B2 JP3982889B2 (en) | 2007-09-26 |
Family
ID=18350025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP34195097A Expired - Lifetime JP3982889B2 (en) | 1997-11-28 | 1997-11-28 | Pharmaceutical preparations containing ibuprofen |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3982889B2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006001920A (en) * | 2004-05-18 | 2006-01-05 | Grelan Pharmaceut Co Ltd | Medicinal preparation |
| JP2009508916A (en) * | 2005-09-22 | 2009-03-05 | レキット ベンキサー ヘルスケア （ユーケイ） リミテッド | Composition containing NSAID and paracetamol |
| US8580856B2 (en) | 2006-10-20 | 2013-11-12 | Ncneil-Ppc, Inc. | Acetaminophen/ibuprofen combinations and method for their use |
| US10532036B2 (en) | 2004-07-07 | 2020-01-14 | Aft Pharmaceuticals Limited | Combination composition |
| US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| CN114031515A (en) * | 2021-11-29 | 2022-02-11 | 河北大学 | Paracetamol-ibuprofen pharmaceutical co-crystal and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008056701A (en) * | 2007-11-16 | 2008-03-13 | Aska Pharmaceutical Co Ltd | Ibuprofen-containing pharmaceutical preparation |
-
1997
- 1997-11-28 JP JP34195097A patent/JP3982889B2/en not_active Expired - Lifetime
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006001920A (en) * | 2004-05-18 | 2006-01-05 | Grelan Pharmaceut Co Ltd | Medicinal preparation |
| US10532036B2 (en) | 2004-07-07 | 2020-01-14 | Aft Pharmaceuticals Limited | Combination composition |
| JP2009508916A (en) * | 2005-09-22 | 2009-03-05 | レキット ベンキサー ヘルスケア （ユーケイ） リミテッド | Composition containing NSAID and paracetamol |
| US8580856B2 (en) | 2006-10-20 | 2013-11-12 | Ncneil-Ppc, Inc. | Acetaminophen/ibuprofen combinations and method for their use |
| US8580855B2 (en) | 2006-10-20 | 2013-11-12 | Mcneil-Ppc, Inc. | Acetaminophen / ibuprofen combinations and method for their use |
| US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| US11534407B2 (en) | 2019-02-27 | 2022-12-27 | Aft Pharmaceuticals Limited | Pharmaceutical compostion containing acetominophen and ibuprofen |
| US11872317B2 (en) | 2019-02-27 | 2024-01-16 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetominophen and ibuprofen |
| CN114031515A (en) * | 2021-11-29 | 2022-02-11 | 河北大学 | Paracetamol-ibuprofen pharmaceutical co-crystal and preparation method thereof |
| CN114031515B (en) * | 2021-11-29 | 2022-10-21 | 河北大学 | Acetaminophen-ibuprofen pharmaceutical co-crystal and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3982889B2 (en) | 2007-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1313133C (en) | Therapeutic agents | |
| CN101073563B (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| JP3667381B2 (en) | Antipyretic analgesic | |
| EP0249347A2 (en) | Controlled release dihydrocodeine composition | |
| JPH05194227A (en) | Chemical | |
| JP2019019132A (en) | Stable pharmaceutical composition | |
| JPH06504543A (en) | Orally administrable pharmaceutical formulation for treating central dopamine deficiency conditions | |
| JP5296968B2 (en) | Oral pharmaceutical composition containing ibuprofen | |
| JP3982889B2 (en) | Pharmaceutical preparations containing ibuprofen | |
| US3094464A (en) | Aspirin-antacid polysiloxane tablet | |
| JPH05246845A (en) | Antipyretic analgesic agent containing ibuprofen | |
| JPH0140009B2 (en) | ||
| JP4913359B2 (en) | Ibuprofen-containing pharmaceutical composition | |
| JPH0656677A (en) | Antacid composition | |
| JP4947609B2 (en) | Antipyretic analgesic composition | |
| JPS6296424A (en) | Improved antiinflammatory composition | |
| JP2007137896A (en) | Ibuprofen-containing pharmaceutical preparation | |
| JP2013049729A (en) | Pharmaceutical composition | |
| JP2584636B2 (en) | Gastritis treatment | |
| JP2000095707A (en) | Oral dissolution type or chewing type solid internal medicine composition containing medicine having bitterness | |
| GB2197198A (en) | Analgesic preparations | |
| JP2005289906A (en) | Medicinal composition | |
| AU777223B2 (en) | Medicaments | |
| JP2000229853A (en) | Menstruation pain-improving composition | |
| JP6804190B2 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20051021 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060707 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070327 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070515 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070515 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070626 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070703 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100713 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20180713 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term |